Institutional Money Flows Into AI Infrastructure and Healthcare Leaders
Big money is signaling a risk-on appetite as Investor’s Business Daily’s proprietary screen for stocks that funds are buying highlights a dozen names hovering near legitimate buy points. Four standout names dominate the current list: Hewlett Packard Enterprise (HPE), Coherent (COHR), Amphenol (APH), and obesity-drug powerhouse Eli Lilly (LLY).
The convergence of three critical AI infrastructure players alongside a pharmaceutical giant underscores a broadening market leadership beyond the usual mega-cap technology suspects. While Eli Lilly continues to benefit from unprecedented demand for GLP-1 weight-loss and diabetes treatments, the presence of HPE, Coherent, and Amphenol highlights institutional conviction in the physical backbone of the artificial intelligence build-out.
Why These Three AI Infrastructure Names Matter Now
Hewlett Packard Enterprise (HPE) has successfully pivoted toward high-performance computing and AI-native server architectures. Its liquid-cooled Cray EX supercomputers and GreenLake hybrid-cloud platform position it as a key vendor for enterprises and hyperscalers deploying large language models. Fund accumulation suggests confidence in HPE’s ability to capture incremental AI server spend.
Coherent (COHR) supplies transceivers, lasers, and optical components essential for high-speed data center interconnects. As AI clusters scale from thousands to hundreds of thousands of GPUs, optical bandwidth demand grows exponentially. Coherent’s vertical integration in indium phosphide and silicon photonics gives it a structural margin advantage.
Amphenol (APH) provides high-speed interconnect solutions—cables, connectors, and backplane assemblies—that form the nervous system of AI data centers. Its broad exposure across communications, industrial, and automotive end-markets diversifies revenue, while its IT datacom segment rides the AI infrastructure wave directly.
Eli Lilly: The Non-Tech Anchor
Eli Lilly’s inclusion reminds investors that secular growth stories exist outside semiconductors. Mounjaro and Zepbound have created a multi-year revenue runway in a metabolic disease market measured in hundreds of billions. Fund ownership of LLY reflects both defensive characteristics and explosive top-line growth—a rare combination.
Screen Methodology and Market Context
IBD’s “Stocks Funds Are Buying” screen identifies companies with rising institutional ownership, strong earnings momentum, and chart patterns constructive for new highs. The current list’s composition suggests fund managers are allocating across the AI value chain—compute (HPE), optics (COHR), connectivity (APH)—while maintaining exposure to best-in-class healthcare innovation (LLY).
Notably, all four stocks are forming or refining bases near prior resistance levels, offering defined risk/reward entry points for rules-based investors. The screen’s appearance coincides with improving market breadth and a constructive “Market in Confirmed Uptrend” status per IBD’s The Big Picture column.
Key Takeaways for Investors
- Institutional sponsorship is broadening from pure-play AI chips to the full infrastructure stack.
- HPE, COHR, and APH represent complementary, non-overlapping exposure to data center build-out.
- Eli Lilly provides sector diversification with comparable fundamental momentum.
- All four names appear on IBD’s Screen of the Day, signaling alignment of fundamentals and technicals.
Frequently Asked Questions
What is IBD’s “Stocks Funds Are Buying” screen?
It is a proprietary filter that identifies stocks showing quarter-over-quarter increases in mutual fund ownership, combined with strong earnings growth, rising relative strength, and proper base construction. The screen aims to reveal where professional capital is concentrating.
Why are data center infrastructure stocks attracting fund interest now?
Hyperscalers (Microsoft, Amazon, Google, Meta) have guided to elevated capital expenditure through 2025 and beyond, specifically for AI-optimized servers, optical networking, and high-density cabling. Companies enabling this build-out—servers, optics, interconnects—are seeing order visibility extend multiple quarters.
How does Eli Lilly fit into an AI-focused screen?
The screen is sector-agnostic; it selects for institutional accumulation and technical/ fundamental criteria regardless of industry. Eli Lilly qualifies due to exceptional earnings growth driven by GLP-1 drugs, massive fund inflows, and a chart pattern that meets IBD’s buy-point rules. Its presence signals broad-based institutional risk appetite.
